Core Viewpoint - The fund "永赢睿信混合A" has rapidly increased its scale and performance, achieving a fund size close to 150 billion by the end of 2025 and a remarkable return of 93.34% in 2025 [3][10]. Fund Performance and Growth - The fund's scale grew significantly from 13.2 billion at the end of 2024 to nearly 150 billion by December 26, 2025, driven by strong performance and institutional investment [3][5]. - The fund's return rate for 2024 was 15.3%, slightly outperforming the benchmark and the CSI 300 index [10][13]. - The fund's turnover rate was approximately 800% in the past two reporting periods, indicating high trading activity [21][22]. Investor Composition - Institutional investors have significantly increased their holdings, reaching 85.9% by mid-2025, while individual investors hold only 14.05% [5][6]. - The number of individual account holders decreased from 1,336 in 2024 to 233,869 in mid-2025, reflecting a shift towards institutional investment [5]. Fund Management - The fund is managed by Gao Nan, who has a history of managing multiple funds, with mixed performance results in previous roles [8][10]. - Gao Nan's strategy involved increasing allocations in the pharmaceutical sector and reducing exposure to electronics, capitalizing on market trends [14][21]. Sector Allocation and Stock Performance - The fund's top holdings include leading stocks in the pharmaceutical and communication sectors, with significant gains in companies like 中际旭创 and 新易盛 [14][18]. - The fund also benefited from investments in the metals sector, with stocks like 紫金矿业 and 华锡有色 achieving over 100% growth [15][18]. Risk and Volatility - The fund has experienced a maximum drawdown of nearly 16% since its inception, indicating potential volatility [19]. - The concentration of holdings in popular stocks may lead to increased volatility and divergence in performance in the future [21].
机构投资者疯狂买入，牛市里牛基的作业能抄吗？|1分钟了解一只吾股好基（七十二）
市值风云·2025-12-29 10:08